Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | PLG | P00747 | 1/20 | 0.75 |
| ▸ | PLAT | P00750 | 1/20 | 0.75 |
| ▸ | GABRR1 | P24046 | 5/20 | 0.46 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 2/20 | 0.44 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954120 | 1.00 | LMNA (0.75) | LMNAPLGPLATGABRR1GABRR2 | |
| SCHEMBL4350693 | 1.00 | LMNA (0.75) | LMNAPLGPLATGABRR1GABRR2 | |
| SCHEMBL28816390 | 1.00 | LMNA (0.75) | LMNAPLGPLATGABRR1GABRR2 | |
| SCHEMBL5722332 | 1.00 | LMNA (0.75) | LMNAPLGPLATGABRR1GABRR2 | |
| SCHEMBL5503267 | 0.87 | LMNA (0.57) | LMNAPLGPLATGABRR1GABRR2 | |
| SCHEMBL9294167 | 0.87 | LMNA (0.57) | LMNAPLGPLATGABRR1GABRR2 | |
| SCHEMBL9504278 | 0.87 | LMNA (0.57) | LMNAPLGPLATGABRR1GABRR2 | |
| SCHEMBL30484839 | 0.87 | LMNA (0.57) | LMNAPLGPLATGABRR1GABRR2 | |
| SCHEMBL5503262 | 0.87 | LMNA (0.57) | LMNAPLGPLATGABRR1GABRR2 | |
| SCHEMBL9504271 | 0.87 | LMNA (0.57) | LMNAPLGPLATGABRR1GABRR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4006080-A1 | COMPOSITIONS, METHODS, AND ARTICLES RELATING TO IN-SITU CROSSLINKING OF POLYAMIDES DURING ADDITIVE MANUFACTURING | Xerox Corporation (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220010032-A1 | PEPTIDE-NUCLEIC ACID COMPLEX | KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION (JP) | 2022-01-13 | — | — | US | disclosed |
| EP-2708569-B1 | TRANSPARENT POLYAMIDE-IMIDES | EMS PATENT AG (CH) | 2018-05-23 | — | — | EP | disclosed |
| US-20170226159-A1 | METHOD FOR PRODUCING HYDROPHOBIC PEPTIDE | KANEKA CORPORATION (JP) | 2017-08-10 | — | — | US | disclosed |
| US-9422429-B2 | Transparent polyamide-imides | EMS-PATENT AG (CH) | 2016-08-23 | — | — | US | disclosed |
| US-20160222210-A1 | TRANSPARENT POLYAMIDE-IMIDES | EMS-PATENT AG (CH) | 2016-08-04 | — | — | US | disclosed |
| CN-103665378-B | Transparent polyamide-imide | EMS PATENT AG (CH) | 2016-01-20 | — | — | CN | disclosed |
| CN-103665378-A | Transparent polyamide-imides | EMS PATENT AG | 2014-03-26 | — | — | CN | disclosed |
| EP-2708569-A1 | Transparent polyamidimide | EMS-PATENT AG (CH) | 2014-03-19 | — | — | EP | disclosed |
| US-20140072745-A1 | TRANSPARENT POLYAMIDE-IMIDES | EMS-PATENT AG (CH) | 2014-03-13 | — | — | US | disclosed |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
| EP-1250340-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| US-6410594-B1 | VIRICIDES | BIOCRYST PHARMACEUTICALS, INC. | 2002-06-25 | — | — | US | disclosed |
| WO-2001046199-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-0933993-A1 | SUBSTITUTED CYCLOPENTANE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS INC. (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1997047194-A1 | SUBSTITUTED CYCLOPENTANE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-12-18 | — | — | WO | disclosed |
| EP-0329105-B1 | MOLECULAR WEIGHT CONTROLLER FOR POLYMERIZATION OF LACTAMS TO POLYAMIDES | BASF Corporation (US) | 1993-07-07 | — | — | EP | disclosed |
| US-5006635-A | Monofunctional amine, monofunctional acid, salt of aminoacid, polyamides | BASF CORPORATION (US) | 1991-04-09 | — | — | US | disclosed |
| EP-0329105-A2 | Molecular weight controller for polymerization of lactams to polyamides | BASF Corporation (US) | 1989-08-23 | — | — | EP | disclosed |
| US-4844834-A | Molecular weight controller for polymerization of lactams to polyamides | BASF CORPORATION (US) | 1989-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ABCC1, ABCB11, ABCB1 | LMNA 2226/4885PLG 2533/4885PLAT 2674/4885 |
| US-20170226159-A1 | METHOD FOR PRODUCING HYDROPHOBIC PEPTIDE | VIP, HM13, HDGF | LMNA 1444/4885PLG 84/4885PLAT 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.